point of care
The company will use the funds to enhance the development of its AI capabilities and for commercial growth.
The pharma giant will also pay $55 million to fund the point-of-care diagnostics platform until the acquisition closes, which is expected to occur by mid-2024.
The company's complete blood count analyzer uses artificial intelligence to quickly measure biomarkers from a fingerstick or venous sample.